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antibodies is thought to be relatively rare. Current
studies of such ‘double-positive’ cases report small
numbers and variable outcomes. To study this further we
retrospectively analyzed clinical features and long-term
outcomes of a large cohort of 568 contemporary patients
with ANCA-associated vasculitis, 41 patients with anti-
GBM disease, and 37 double-positive patients with ANCA
and anti-GBM disease from four European centers.
Double-positive patients shared characteristics of
ANCA-associated vasculitis (AAV), such as older age
distribution and longer symptom duration before
diagnosis, and features of anti-GBM disease, such as
severe renal disease and high frequency of lung
hemorrhage at presentation. Despite having more
evidence of chronic injury on renal biopsy compared to
patients with anti-GBM disease, double-positive patients
had a greater tendency to recover from being dialysis-
dependent after treatment and had intermediate long-
term renal survival compared to the single-positive
patients. However, overall patient survival was similar in
all three groups. Predictors of poor patient survival
included advanced age, severe renal failure, and lung
hemorrhage at presentation. No single-positive anti-GBM
patients experienced disease relapse, whereas
approximately half of surviving patients with AAV and
double-positive patients had recurrent disease during a
median follow-up of 4.8 years. Thus, double-positive
patients have a truly hybrid disease phenotype, requiring
aggressive early treatment for anti-GBM disease, and
careful long-term follow-up and consideration for
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A nti-glomerular basement membrane (GBM) diseaseand the anti-neutrophil cytoplasm antibody(ANCA)-associated vasculitides (AAV) are rare con-
ditions, with estimated incidences in Europe of 1 and 20
per million population per year, respectively.1,2 The concur-
rence of both ANCA and anti-GBM antibodies in individual
patients, however, is well-recognized, and occurs at a much
higher frequency than would be expected by chance alone.
This phenomenon was ﬁrst reported within a few years of
the ﬁrst description of ANCA in the 1980s,3,4 and has
been observed in several series from around the world
over the subsequent 30 years.5–8 It is clear that the 2 anti-
body populations associated with these diseases are antigen-
ically distinct,9 and that this phenomenon is not due to
cross-reactivity, although the mechanisms of the association
are not fully understood.
Several studies have reported the outcomes of these patients
who are double positive, although with conﬂicting ﬁndings;
some have observed better outcomes comparedwith those with
single-positive anti-GBM disease,4,10,11 while others have sug-
gested that patients who are double positive have comparable
or worse outcomes.5,6,12–16 These studies, however, have
generally been limited by small size (many describing fewer
than 20 cases) and variations in the severity of disease at pre-
sentation, with between 0% and 100% of patients being
dependent on dialysis at diagnosis.8,15 Furthermore, in the
largest series to date, from Chinese centers, fewer than 25% of693
Table 1 | Case identiﬁcation, demographics, clinical features, and serology
AAV Anti-GBM Double positive
P value
AAV
versus
DP
versus
GBM
AAV
versus
DP
GBM
versus
DP
AAV
versus
GBM
Cases, n 568 41 37 – – – –
 United Kingdom 171 19 20
 Sweden 100 13 8
 Czech Republic 297 9 9
Cases, % 87.9% 6.3% 5.7%
Demographics
Age, yr (range) 62.3 (11–95) 58.3 (13–91) 63.6 (17–88) 0.17 0.99 0.31 0.21
Gender
 Male 54% 46% 38% 0.11 0.06 0.49 0.34
 Female 46% 54% 62%
Clinical Features
Duration of symptoms,a wk (range) 12 (0–56) 2 (0–20) 10 (1–26) <0.01 0.99 <0.01 <0.01
Lung
hemorrhage
131/568
23%
16/41
40%
14/37
38%
0.01 0.04 0.85 0.02
Required RRT at
presentation
132/568
23%
26/41
63%
21/37
57%
<0.01 <0.01 0.55 <0.01
eGFR,b ml/min (range) 29 (5–90) 20 (5–90) 19 (6–76) 0.06 0.11 0.99 0.67
Serum creatinine,b mmol/l (range) 186 (39–693) 275 (62–667) 309 (71–606) 0.06 0.18 0.99 0.37
Serology
Anti-GBM level, xULN (range) – 5.4 (1–29.1) 14.2 (1–50.4) – 0.06 –
Proportion seronegative for anti-GBM, % – 4/41
11%
4/37
11%
– 1.00 –
ANCA serology, % <0.01 – –
 Anti-MPO 48% 70%
 Anti-PR3 51% 27%
 Anti-MPO & PR3 <1% (n ¼ 2) 3%
AAV, anti-neutrophil cytoplasm antibody–associated vasculitis; DP, double-positive; eGFR, estimated glomerular ﬁltration rate; GBM, glomerular basement membrane; MPO,
myeloperoxidase; PR3, proteinase 3; RRT, renal replacement therapy; xULN, multiples of upper limit of normal.
Results expressed as median  range. Comparison between groups by Kruskall–Wallis test with Dunn’s post-test to ascertain differences between individual groups (for
continuous data), or by chi-square test (for categorical data).
aCalculated for a sample of 48 ANCA cases.
bCensored for patients on RRT.
c l i n i ca l i nves t iga t i on SP McAdoo et al.: Double-positive ANCA and anti-GBM diseasepatients were treated with plasma exchange, and so the appli-
cability of the ﬁndings to European patients treated with sub-
stantially different therapeutic regimens is limited.7,16
The aim of the present study is to describe the clinical
features and long-term outcomes of a contemporary cohort
of patients with double-positive ANCA and anti-GBM dis-
ease. Given the rarity of these patients, we have identiﬁed
cases from 4 large Northern European nephrology centers,
which employ comparable treatment protocols for these
cases, including plasma exchange, cyclophosphamide, and
steroids, unless contraindicated. We have compared clinical
features and outcomes to those for single-positive AAV and
single-positive anti-GBM disease. Because patients with
double-positive disease more closely resemble those with
single-positive anti-GBM disease at presentation, we have
also compared histopathology and treatment in these 2
groups.
RESULTS
Case identiﬁcation and demographics
Between 2000 and 2013, a total of 646 cases were identiﬁed at
4 centers in 3 countries, including 568 patients with694single-positive AAV, 41 with single-positive anti-GBM disease,
and 37 patients who were double positive for anti-GBM
antibodies and ANCA (hereafter AAV, anti-GBM, and
double-positive groups, respectively) (Table 1). The ratio of
double-positive to single-positive anti-GBM cases was similar
in all 3 countries (47% overall); however, patients who were
double positive represented a variable proportion of the AAV
cases (3% to 10.5%; 6.1% overall). The demographic features
of the cohort are summarized in Table 1. The single-positive
anti-GBM group demonstrated the typical bimodal age dis-
tribution of this disease, whereas patients who were double
positive had an age distribution similar to patients with iso-
lated AAV (Figure 1). There was no signiﬁcant difference in
gender ratio between the 3 groups. Notably, 1 patient in the
double-positive group had a previous diagnosis of isolated
anti-myeloperoxidase (MPO) and AAV 2 years prior to pre-
senting with double-positive disease.
Clinical presentation and serology
Table 1 summarizes key clinical features and serological
ﬁndings at presentation. The duration of symptoms
prior to receiving a diagnosis was similar in the AAV andKidney International (2017) 92, 693–702
Figure 1 | Age distribution of patients with anti–glomerular
basement membrane (GBM) disease, anti-neutrophil cytoplasm
antibody–associated vasculitis (AAV), and double positive
disease at presentation.
SP McAdoo et al.: Double-positive ANCA and anti-GBM disease c l i n i ca l i nves t iga t iondouble-positive groups (median: 10–12 weeks), and this was
signiﬁcantly longer than in single-positive anti-GBM patients
(2 weeks; P < 0.01). Despite shorter duration of symptoms,
the severity of disease—whether deﬁned as need for hemo-
dialysis or, in patients who were not dialysis-dependent, by
GFR estimations or serum creatinine measurements—in anti-
GBM patients was similar to that of patients who were double
positive. The frequency of alveolar hemorrhage was similar in
anti-GBM and double-positive groups, occurring in about
one-third of patients. Severe disease manifestations (dialysis
requirement and lung hemorrhage) were less common in
patients with AAV, each occurring in approximately one-
quarter of cases. Patients who were double positive had
additional extrarenal manifestations, including non-
hemorrhage lower respiratory tract disease (in 26%),
otorhinolaryngological involvement (18%), musculoskeletal
symptoms (18%), cutaneous features (13%), neurological
(8%), gastrointestinal (5%), and ocular symptoms (3%).
Because a variety of anti-GBM assays were used during the
study period and at different hospital sites, results were
standardized by expressing them as multiples of the upper
limit of normal (xULN) for each assay. Patients who were
double positive tended to have lower levels of circulating anti-
GBM antibodies than did anti-GBM patients who were single
positive, although the difference between groups was not
statistically signiﬁcant. A similar proportion of patients in
both these groups (approximately 10%) were seronegative for
circulating anti-GBM antibodies. In these cases, there was
convincing evidence of linear IgG deposition on renal biopsy,
in the absence of another attributable cause, in keeping with
our deﬁnition of anti-GBM disease.
In the AAV group, the proportion of patients who were
positive for anti-proteinase 3 (PR3) versus anti-MPO anti-
body was approximately equal. However, in the double-
positive groups there was a comparative over-representation
of patients with anti-MPO antibodies (70% vs. 48%,
P < 0.01). One patient in the double-positive group was triple
positive for anti-MPO, anti-PR3, and anti-GBM antibodies.
Notably, this patient had a history of recreational drug use
and was positive for hepatitis C virus. Because a variety of
methodologies, including indirect immunoﬂuorescence and
antigen-speciﬁc assays, were used to conﬁrm ANCA positivity
over the period of the study, it was not possible to standardize
comparisons of ANCA titer.
Histopathology
Because the anti-GBM and double-positive groups had similar
disease severity at presentation, we performed more detailed
analysis to compare histopathological and therapeutic differ-
ences in these 2 cohorts. Approximately two-thirds of patients
in both groups underwent renal biopsy, as described in Table 2.
The severity of renal disease in those who underwent biopsy
was similar in both groups and equivalent to the severity of
renal disease in the parent cohort, suggesting that biopsy
ﬁndings may be representative and comparable between
groups. It was not possible, however, to retrospectively identifyKidney International (2017) 92, 693–702the reasons why renal biopsy was not undertaken in all
remaining patients. In some cases, this was due to the need for
immediate treatment with plasma exchange, and others were
considered too clinically unstable for biopsy. In keeping with
the age difference between the parent groups, the mean age in
the subset of patients who underwent biopsy was lower in the
anti-GBM group compared with the double-positive group.
The median number of glomeruli in each biopsy was 15
(interquartile range: 10–20). There was no difference in the
proportion of crescentic glomeruli between the 2 groups.
There was, however, a tendency for more sclerotic glomeruli
to be observed in patients who were double positive (median:
15% vs. 0%; P ¼ 0.188). Likewise, the ﬁnding of “synchro-
nous” crescent formation tended to be more commonly
observed in patients with anti-GBM disease (73% vs. 33% in
patients who were double positive; P ¼ 0.092). There was a
highly signiﬁcant difference in the degree of interstitial
ﬁbrosis and tubular atrophy between these 2 groups, with
more evidence of chronic damage in double-positive cases
(median: 27% vs. 5%, P < 0.001). In those cases in which
adequate tissue was available for analysis, all but 3 cases (2
double-positive, 1 single-positive for anti-GBM, and all with
circulating anti-GBM antibodies) had linear deposition of IgG
by immunoﬂuorescence analysis of the kidney biopsy.
Treatment
There was no detectable difference between single-positive
anti-GBM and double-positive groups with regard to initial
treatment administered, the majority receiving standard of
care with steroids (97% vs. 100% in double-positive and anti-
GBM cases, respectively; P ¼ 0.47), cyclophosphamide (100%
vs. 92%; P ¼ 0.24), and plasma exchange (80% vs. 89%; P ¼
0.33). In total, 10 patients did not undergo plasma exchange
for various reasons. In the double-positive group, 7 patients
did not receive plasma exchange. Of these, 2 were dialysis
dependent at presentation with 100% crescent formation on
kidney biopsy, and in the absence of lung hemorrhage, plasma
exchange was deemed futile. These patients received cytotoxic
therapy and steroids for nonrenal manifestations. Of the695
Table 2 | Histopathology
Anti-GBM Double positive P value
Underwent biopsy, n (%) 29 (71%) 25 (68%) 0.81
Mean age at biopsy, yr (range) 46 (13–91) 62 (46–76) <0.01
Renal status at biopsy
 Required RRT 52% 54% 1.00
 eGFR,a ml/min (range) 21 (5–90) 16 (8–73) 0.78
 Serum creatininea
mmol/l (range)
275 (62–677) 315 (71–606) 0.75
Glomerular ﬁndings
 Crescentic glomeruli, % 64% (0–100) 64% (25–100) 0.98
 Sclerotic glomeruli, % 0% (0–80) 15% (0–100) 0.19
 Normal glomeruli, % 5% (0–100) 0% (0–67) 0.56
Tubular atrophy, % (range) 5% (0%–30%) 27% (0%–80%) <0.01
Immunoﬂuorescence pattern 0.69
 Linear IgG 79% 80%
 Pauci-immune 3% 8%
 Technically inadequate 17% 12%
eGFR, estimated glomerular ﬁltration rate; GBM, glomerular basement membrane;
RRT, renal replacement therapy.
Results expressed as median  range. Comparison between groups by Mann-
Whitney test (for continuous data), or by chi-square test (for categorical data).
aCensored for patients on RRT.
c l i n i ca l i nves t iga t i on SP McAdoo et al.: Double-positive ANCA and anti-GBM diseaseother 5 patients, none had alveolar hemorrhage or required
dialysis, and their initial treatment was typical of those pre-
senting with isolated AAV. In the single-positive anti-GBM
group, 1 patient was dialysis dependent with no normal
glomeruli on kidney biopsy, and so treatment was deemed
futile; 1 patient had well-preserved renal function (serum
creatinine: 78 mmol/l) and so plasma exchange was initially
reserved for nonresponse to immunosuppressive treatment
alone, and was ultimately not required; and 1 patient was
clinically unstable and therefore unable to undergo plasma
exchange.
At 6 months, 74% of patients who were double positive
were receiving ongoing immunosuppressive treatment with
or without corticosteroids (71% with azathioprine, 21% with
mycophenolate mofetil, and 8% with methotrexate), whereas
only 14% of patients with single-positive anti-GBM disease
received ongoing therapy (P < 0.001), of whom 80% received
azathioprine and 20% received MMF.
Outcomes
Patient and renal survival for all 3 cohorts at 3 and 12months is
summarized in Table 3. Overall patient survival was similar in
all groups at both time points. Renal survival was favorable in
the AAV group at both time points, although there was no
signiﬁcant difference in the proportion of patients who
required dialysis in the anti-GBM and double-positive group at
either time point. The proportion of patients who presented
with dialysis-dependent renal failure and who recovered renal
function and were alive at 1 year was signiﬁcantly different
between groups, varying from 17% in patients with single-
positive anti-GBM disease to 29% in patients who were dou-
ble positive and 49% in AAV cases. As Figure 2 demonstrates,
this was due in part to cross-over from dialysis dependence to
independence, and vice versa, particularly within the double-
positive group, in which a substantial proportion recovered696renal function in the ﬁrst 3 months of follow-up (35% recovery
vs. 10% recovery in patients who were single positive; P ¼
0.11). There was no signiﬁcant difference in age (mean: 65 vs.
64 years; P ¼ 0.88) or receipt of plasma exchange (100% vs.
82%; P ¼ 0.52) between those patients and who were double-
positive and who recovered and those who did not, respec-
tively, although those who recovered renal function tended to
have lower levels of anti-GBM antibodies (3.8 vs. 10 xULN,
respectively; P¼ 0.07). Only one-half of the patients who were
double-positive who recovered renal function underwent renal
biopsy, and so it was not possible to reliably identify histo-
pathological predictors of treatment response.
The median duration of follow-up was 4.8 years (range:
0–15 years). Long-term patient and renal survival is sum-
marized in Figure 3a and b, respectively. No difference in
unadjusted overall patient survival was observed during the
study (P ¼ 0.49). Renal survival was favorable in the AAV
group compared with both the anti-GBM group (P < 0.01)
and the double double-positive groups (P < 0.01). Patients
who were double positive tended to have better renal survival
than those who were single positive with anti-GBM disease,
although this difference was not statistically signiﬁcant in
unadjusted analysis (P ¼ 0.17).
Relapse
Relapse data were available in 316 AAV patients and all patients
with anti-GBM disease and double positivity until last follow-
up. Within the follow-up period, 116 of 316 patients with AAV
(37%) and 8 of 37 patients who were double positive (22%)
had a relapse. Two patients with single-positive anti-GBM
disease had early recrudescence of anti-GBM antibodies
requiring augmented treatment in the ﬁrst 6 months following
initial diagnosis, which we believe reﬂected inadequate initial
disease control rather than disease relapse. No patients with
single-positive anti-GBM disease exhibited evidence of relapse
or recurrent antibodies beyond 6 months. During long-term
follow-up, a signiﬁcant proportion (n ¼ 8; approximately
50%) of the surviving patients who were double positive
developed recurrent disease (Figure 3c). These relapses tended
to occur late (median time to ﬁrst relapse: 4.4 years; range: 1.1–
7.9 years), and the majority (5 of 8) were in patients with
ANCAdirected against PR3, in keeping with the natural history
of isolated AAV. Two patients had relapses associated with
MPO-ANCA, and 1 notable patient had a relapse of both
MPO-ANCA and anti-GBM antibodies. All relapses occurred
in patient who were ANCA positive, and the majority (6 of 8)
were associated with a rise in ANCA titer of more than 25%, or
seroconversion from ANCA-negative to ANCA-positive status,
in the 6 months prior to diagnosis of relapsing disease. Table 4
summarizes the clinical features of each relapse and its relation
to immunosuppressive treatment. Notably, the majority of
patients were not receiving maintenance treatment other than
corticosteroids at the time of relapse. As shown in Figure 3c, the
frequency of relapse in the double-positive cohort was com-
parable to that in AAV cases (P¼ 0.29), whereas there were no
relapses in the anti-GBM group (P < 0.01). Two patients whoKidney International (2017) 92, 693–702
Table 3 | Patient and renal survival at 3 and 12 months after diagnosis
Diagnosis
0 Months 3 months 12 months
Renal recovery at 1 yearbIndependent of RRT Patient survival Renal survivala Patient survival Renal survivala
AAV 437/568
77%
540/568
95%
490/540
91%
512/568
90%
452/512
88%
64/131
49%
Anti-GBM 15/41
37%
37/41
90%
15/36
42%
36/41
87%
15/34
44%
4/24
17%
Double positive 16/37
43%
33/37
89%
16/32
50%
31/37
83%
16/30
53%
6/21
29%
P value <0.01 0.13 <0.01 0.38 <0.01 <0.01
AAV, anti-neutrophil cytoplasm antibody–associated vasculitis; GBM, glomerular basement membrane; RRT, renal replacement therapy.
Comparison between groups by chi-square test.
aCensored for death.
bProportion of patients requiring RRT at presentation who were alive with independent renal function at 1 year.
SP McAdoo et al.: Double-positive ANCA and anti-GBM disease c l i n i ca l i nves t iga t ionwere double positive have undergone renal transplantation. To
date, no disease recurrence related to either ANCA or anti-
GBM disease has been described in the renal allografts.
Predictors of death, ESRD, and relapse
There were signiﬁcant differences in age, proportion of pa-
tients requiring renal replacement therapy (RRT), and pro-
portion of patients with lung hemorrhage at presentation
between patients diagnosed with AAV, anti-GBM disease, and
double positivity. We therefore performed regression analysis
to identify predictors of death and end-stage renal disease
(ESRD) in all patients, correcting for these differences in
baseline variables (Table 5; Figure 4).
Unadjusted predictors of death included RRT at presen-
tation (hazard ratio [HR]: 2.2 [1.63–2.97]; P < 0.01), lung
hemorrhage (HR: 1.45 [1.06–1.99]; P ¼ 0.02), and age (HR:
1.05 [1.04–1.06]; P < 0.01), but not diagnosis. In multivari-
able analysis, RRT at presentation (HR: 2.04 [1.49–2.78],
P < 0.01) and age (HR: 1.05 [1.04–1.06]; P < 0.01) predicted
death. The inﬂuence of lung hemorrhage at presentation (HR:
1.37 [0.99–1.89]; P ¼ 0.06) approached statistical signiﬁ-
cance, while diagnosis had no inﬂuence.
Unadjusted predictors of progression to ESRD included
diagnosis (P < 0.01), lung hemorrhage at presentation (HR:Figure 2 | Transition to and from dialysis dependence in the ﬁrst 3
positive anti–glomerular basement membrane disease cases. Censo
Kidney International (2017) 92, 693–7021.89 [1.32–2.63]; P < 0.01), and RRT at presentation (HR:
9.34 [6.53–13.33]; P < 0.01). Age was not associated with
progression to ESRD (P ¼ 0.18). In multivariable analysis,
RRT at presentation (HR: 7.69 [5.26–11.10]; P < 0.01) and
diagnosis (P < 0.01) increased the HR of progression to
ESRD. The risk of ESRD was increased in anti-GBM disease
compared with AAV (HR: 2.66 [1.69–4.19], P < 0.01), though
the risk in patients who were double positive versus those
with AAV was not signiﬁcantly different (HR: 0.62 [0.36–
1.06]; P ¼ 0.08), suggesting an intermediate risk of ESRD in
patients who were double positive. Age (P ¼ 0.11) and lung
hemorrhage at presentation (P ¼ 0.42) had no inﬂuence on
progression to ESRD.
Unadjusted predictors of a composite outcome of death or
progression to ESRD included age (HR: 1.01 [1.00–1.02];
P¼ 0.01), diagnosis (P< 0.01), RRTat presentation (HR: 5.71
[4.17–15.38]; P < 0.01), and lung hemorrhage at presentation
(HR: 1.79 [1.08–2.94]; P < 0.01). In multivariable analysis,
diagnosis (P < 0.01), RRT at presentation (HR: 4.55 [3.33–
6.25]; P< 0.01), and age (HR: 1.02 [1.01–1.03]; P< 0.01) were
associated with progression to death or ESRD. Lung hemor-
rhage at presentation was not associated with progression to
death or ESRD (P ¼ 0.23). Death or progression to ESRD was
similar between double-positive and single-positive anti-GBMmonths (mo) following treatment, in double-positive and single-
red for death in the ﬁrst 3 months.
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Figure 3 | Unadjusted Kaplan–Meier survival functions describing
long-term patient, renal, and relapse-free survival rates of the
study cohort during 10 years’ follow-up. (a) Overall patient
survival. (b) End-stage renal disease-free survival. (c) Relapse-free
survival (censored for death). AAV, anti-neutrophil cytoplasm anti-
body–associated vasculitis; DP, double positive; ESRD, end-stage
renal disease; GBM, glomerular basement membrane.
c l i n i ca l i nves t iga t i on SP McAdoo et al.: Double-positive ANCA and anti-GBM diseasedisease cases. However, patients with AAV had a lower hazard
ratio of progression to ESRD or death compared with patients
who were double positive (HR: 0.57 [0.35–0.93]; P ¼ 0.02).698Unadjusted predictors of relapse included diagnosis
(P< 0.01), and RRT dependence at presentation was associated
with a lower risk of relapse (P¼ 0.02). Further analysis was not
conducted due to the relative small number of relapse episodes.
DISCUSSION
This is the largest published series to compare the outcomes of
patients with both ANCA and anti-GBM autoantibodies with
patients with single-positive AAV and anti-GBM disease. As
such, it provides several important observations: the phenom-
enon of double positivity is common, these patients experience
the early morbidity and mortality typical of anti-GBM disease,
and they carry the long-term risk of relapse typical of AAV.
Patients who are double positive accounted for
approximately one-half of all anti-GBM disease cases seen
at our centers since 2000, and over 10% of AAV patients
with renal involvement seen at the UK site over the same
time period. The proportion of AAV cases was variable at
the other sites, perhaps reﬂecting differences in referral
pattern at each (with varying proportions of patients with
extrarenal vasculitis) and differences in sensitivity of assays
used to detect ANCA, or geographical variations in disease
frequency. Notably, a recent study reported that more than
60% of patients with anti-GBM disease had autoantibodies
reactive to linear epitopes of MPO, versus 24% who had
antibodies to native protein detected by conventional as-
says. Our study highlights this common concurrence, and
our observations reiterate the need to determine the
alternative antibody type in all cases of AAV- or anti-GBM
disease.
In this large series, we observed comparable severity of
disease at presentation between single-positive anti-GBM and
double-positive cases, with approximately 60% of patients
requiring renal replacement therapy at presentation, and
one-third developing lung hemorrhage, in both groups.
Regression analysis suggests that it is these severe disease
manifestations, rather than diagnosis per se, that affect overall
patient survival, and because they are equally prevalent in pa-
tients with anti-GBMdisease and those who are double positive
(and less frequent than in AAV), this suggests that anti-GBM
disease is the “dominant” early disease phenotype in double-
positive cases. These patients, however, also demonstrate
clinical features of AAV, such as an older age distribution, a
longer prodrome of systemic symptoms, and features of
chronic damage on renal biopsy (in excess of what would be
expected for the age difference between groups). In addition,
regression analysis suggests that patients who are double pos-
itive have an intermediate risk of progression to ESRD
compared with single-positive AAV or anti-GBM cases. This
may be related to the observation that more than one-third of
the surviving patients who were double positive and required
dialysis at presentation regained independent renal function by
3 months. This propensity to renal recovery was more in
keeping with AAV than anti-GBM disease, where regaining
renal function from dialysis is very uncommon,17 and consis-
tent with some previous reports of double-positive cases.4,10,11Kidney International (2017) 92, 693–702
Table 4 | Details of double-positive patients with relapse
Case Time to relapse (months) ANCA GBM Ab Organ involvement Treatment at time of relapse Treatment for relapse Subsequent relapse
1 13 PR3 Neg Renal, skin CS only;
CYC stopped 9 mo prior
CYC, CS Yes
2 16 PR3 Neg LRT CS only;
AZA stopped 4 mo prior
AZA, CS No
3 22 MPO Neg LRT CS only;
AZA stopped 18 mo prior
CS Yes
4 36 PR3 Neg Renal, Skin MMF, CS RTX, CYC, CS Yes
5 71 PR3 Neg Renal AZA AZA, CS No
6 81 PR3 Neg Constitutional CS only;
AZA stopped 10 mo prior
AZA, CS Yes
7 87 MPO Neg Renal None;
off treatment 5 yr
CS No
8 95 MPO Positive LRT, Renal None;
off treatment 12 mo
RTX, CYC, CS No
ANCA, anti-neutrophil cytoplasm antibody; AZA, azathioprine; CS, corticosteroids; CYC, cyclophosphamide; GBM, glomerular basement membrane; LRT, lower respiratory tract;
MPO, myeloperoxidase; MMF, mycophenolate mofetil; mo, months; PR3, proteinase 3; RTX, rituximab; y, years.
SP McAdoo et al.: Double-positive ANCA and anti-GBM disease c l i n i ca l i nves t iga t ionThat our patients who were double positive had this ten-
dency to renal recovery and intermediate long-term renal
survival, despite more chronic renal damage on kidney biopsy
and more advanced age at presentation, is striking. Re-
sponders tended to have lower levels of anti-GBM antibodies,
suggesting that they may have been identiﬁed early in the
course of anti-GBM disease, or that they may have a “milder”
form of disease. Of note, there are several recent reports of
“atypical” variants of anti-GBM disease, each characterized by
less severe renal involvement than is usually observed.18–20
Differences in antibody subclass or in antigen or epitope
speciﬁcity may account for these variable presentations. With
regard to patients who are double positive, 1 previous study
found that they had a broader spectrum of anti-GBM anti-
bodies and lower reactivity to a3(IV)NC1 than patients whoTable 5 | Predictors of death and end-stage renal disease
Unadjusted analysis
Death
HR (CI) P value
Diagnosis – 0.25
DPa versus AAV 0.72 (0.406–1.26) 0.25 0.3
DPa versus GBM 0.78 (0.34–1.79) 0.56 1.54
AAVa versus GBM 1.10 (0.58–2.08) 0.78 4.9
Age at presentation 1.05 (1.04–1.06) <0.01 1.0
RRT at presentation 2.20 (1.63–2.97) <0.01 9.3
LH at presentation 1.45 (1.06–1.99) 0.02 1.8
Multivariable analysis
Death
HR (CI) P value
Diagnosis – 0.95
DPa versus AAV 0.97 (0.52–1.81) 0.92 0.6
DPa versus GBM 0.94 (0.39–2.28) 0.89 1.6
AAVa versus GBM 0.97 (0.48–1.95) 0.93 2.6
Age at presentation 1.05 (1.04–1.06) <0.01 1.0
RRT at presentation 2.04 (1.49–2.78) <0.01 7.6
LH at presentation 1.37 (0.99–1.89) 0.06 1.1
AAV, anti-neutrophil cytoplasm antibody–associated vasculitis; DP, double positive; ESR
hazard ratio; LH, lung hemorrhage; RRT, renal replacement therapy.
aReference group for estimates of hazard ratios.
Kidney International (2017) 92, 693–702were single positive,21 although an earlier study did not report
differences in antigen speciﬁcity.22 It is therefore possible that
differences in antigen or epitope speciﬁcity account for the
difference in treatment response seen in our cohort; however,
we were unable to analyze this in detail in a retrospective
study. Likewise, we have been unable to identify histopatho-
logical predictors of recovery, a signiﬁcant limitation of our
analysis. Previous studies have shown that the proportion of
crescentic and normal glomeruli in anti-GBM disease is
predictive of prognosis,17,23 and a prognostic classiﬁcation
based on histopathological ﬁndings has been proposed for
ANCA-associated glomerulonephritis.24,25 It is unclear,
however, whether these observations apply to patients who
are double positive. Given the overall rarity of anti-GBM
disease, a larger, multicenter analysis of histopathologicalESRD Death or ESRD
HR (CI) P value HR (CI) P value
– <0.01 – <0.01
1 (0.19–0.51) <0.01 0.33 (0.42–0.52) <0.01
2 (0.85–2.80) 0.16 1.38 (0.78–2.45) 0.27
8 (3.25–7.64) <0.01 4.21 (2.78–6.37) <0.01
1 (0.99–1.02) 0.18 1.01 (1.00–1.02) 0.01
4 (6.53–13.33) <0.01 5.71 (4.17–15.38) <0.01
9 (1.36–2.63) <0.01 1.79 (1.32–2.38) <0.01
ESRD Death or ESRD
HR (CI) P value HR (CI) P value
<0.01 – <0.01
2 (0.36–1.06) 0.08 0.57 (0.35–0.93) 0.02
6 (0.88–3.12) 0.12 1.49 (0.82–2.72) 0.19
6 (1.69–4.19) <0.01 2.63 (1.69–4.09) <0.01
1 (1.00–1.02) 0.11 1.02 (1.01–1.03) 0.03
9 (5.26–11.1) <0.01 4.55 (3.33–6.25) <0.01
5 (0.82–1.61) 0.42 1.21 (0.88–1.64) 0.23
D, end-stage renal disease; GBM, anti–glomerular basement membrane disease; HR,
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Figure 4 | Cox proportional hazards regression curves describing long-term risk of (a) death, (b) end-stage renal disease (ESRD), and (c)
death or ESRD. Measures being controlled for include diagnosis, age, requirement for renal replacement therapy at presentation, and presence
of lung hemorrhage at presentation. AAV, anti-neutrophil cytoplasm antibody–associated vasculitis; DP, double positive; GBM, anti-glomerular
basement membrane disease.
c l i n i ca l i nves t iga t i on SP McAdoo et al.: Double-positive ANCA and anti-GBM diseaselesions in these cases is likely needed in order to infer reliable
prognostic indicators. Pending such information, our obser-
vations suggest that while patients who are double positive
behave primarily like those with isolated anti-GBM disease, a
subset of patients who are dialysis dependent at presentation
may be more responsive to therapy, and aggressive treatment
may be warranted in some cases.
The other striking characteristic of AAV retained by
patients who are double positive is a risk of disease relapse.
The long-term follow-up offered by our study suggests that
almost one-half of surviving patients who are double positive
will experience disease relapse at some point, at a frequency
comparable to that observed in our single-positive AAV
cohort. As might be expected, these relapses were more likely
in patients who were anti-PR3 positive, and were associated
with preceding increases in ANCA titer. Of note, 1 patient
relapsed with both ANCA and anti-GBM antibodies. These
observations suggest that while the dominant early disease
phenotype in these patients is anti-GBM disease, unlike
patients with isolated anti-GBM disease these cases require
frequent long-term follow-up and consideration of mainte-
nance immunosuppression. That 1 of our patients had an
earlier diagnosis of isolated AAV prior to presenting with a
double-positive “relapse” also suggests that anti-GBM anti-
bodies should be determined in relapsing AAV cases, partic-
ularly if there is evidence of renal involvement.
The mechanism of association between AAVand anti-GBM
disease in unclear. Studies in animal models suggest that
administration of the alternate antibody type may augment
the severity of renal disease in models of either vasculitis or
anti-GBM nephritis;26–28 however, these in vivo studies have
shed little light on the spontaneous development of both
antibody types, or on the sequence in which they develop in
clinical disease. An elegant clinical study by Olson and col-
leagues, using stored sera from the US Department of Defense,
suggested that the majority of patients with anti-GBM disease700had detectable ANCA prior to the development of anti-GBM
antibodies, which in turn predated the development of clinical
disease, suggesting that AAV may act as trigger for anti-GBM
disease.29 Our observations support this hypothesis: patients
who were double positive had the age restriction of isolated
AAV cases, a longer prodrome of systemic symptoms prior to
diagnosis, and more features of chronicity on their renal
biopsy, suggesting that ANCA-mediated glomerular inﬂam-
mation may precede and contribute to the development of
anti-GBM disease, perhaps by disrupting the quaternary
structure of the GBM.30 This could lead to the exposure of
normally sequestered epitopes in a pro-inﬂammatory milieu,
resulting in a fulminant anti-GBM response. Conversely, it has
been shown that aberrant extracellular expression of myelo-
peroxidase, as a constituent of neutrophil extracellular traps,
may predispose to the development of anti-MPO antibodies,31
and that neutrophil extracellular traps are formed in experi-
mental anti-GBM disease.32 Thus, it is possible that glomer-
ular neutrophil recruitment and activation in anti-GBM
disease similarly contributes to the development of ANCA.
The recent observation that a high proportion of patients with
anti-GBM disease have autoantibodies reactive to linear epi-
topes of MPO might support this hypothesis, as it suggests
reactivity to conformational MPO epitopes might arise as a
consequence of inter- and intramolecular epitope spreading
initiated by anti-GBM disease.33 Whether additional envi-
ronmental or genetic factors predispose to forming both an-
tibodies is unclear. The genetic associations of both anti-GBM
disease and AAV are increasingly well-described,34,35 and both
conditions have strong associations with certain HLA genes.
Notably, both conditions have reported associations with
HLA-DRB1*1501, and a previous small study observed a
DRB1-15 genotype in 4 of the 5 patients who were double
positive that were examined.36
In this descriptive, retrospective study, we have been un-
able to analyze the genetic or detailed serological andKidney International (2017) 92, 693–702
SP McAdoo et al.: Double-positive ANCA and anti-GBM disease c l i n i ca l i nves t iga t ionpathological features of our cohort. Strengths of our study,
however, include its large size, its long follow-up period
beyond 10 years for many patients, the inclusion of all single-
positive anti-GBM and AAV cases by way of controlled
comparison, and that it is multicenter, from international
sites that utilize comparable treatment regimens. We highlight
several important clinical practice points—in particular that
while anti-GBM disease is the predominant disease phenotype
in these patients, their ANCA status should neither be ignored
nor forgotten, because a subset may be more responsive to
initial immunosuppressive treatment, and they have a sig-
niﬁcant risk of relapse requiring careful long-term follow-up
and monitoring.METHODS
This is a retrospective analysis of patients diagnosed with AAV, anti-
GBM disease, and double-positive ANCA and anti-GBM antibody
disease from 4 European centers: Hammersmith Hospital, London,
UK; Charles University Hospital, Prague, Czech Republic; Skånes
University Hospital, Lund, Sweden; and Linköping University Hos-
pital, Linköping, Sweden. All patients diagnosed between 2000 and
2013 with at least 1 year of follow-up were included in analysis.
Patients with a diagnosis of systemic vasculitis consistent with the
Chapel Hill Consensus Conference37 and positive ANCA serology
were included in the AAV group. Anti-GBM disease was deﬁned by
either (i) the presence of circulating anti-GBM antibodies in asso-
ciation with clinical manifestations of alveolar hemorrhage and/or
rapidly progressive glomerulonephritis, or (ii) biopsy-proven cres-
centic glomerulonephritis with linear deposition of IgG along the
GBM in the absence of another attributable cause (such as diabetes
mellitus or paraproteinaemia). The double-positive cohort included
patients who met this diagnosis of anti-GBM disease and in addition
had positive ANCA serology.
Circulating anti-GBM antibodies were identiﬁed using conven-
tional commercially available assays, which varied between site and
over time at each center. Antigen substrates included puriﬁed bovine
or human GBM preparations and recombinant human a3(IV)
collagen chain. ANCA was detected either by indirect immunoﬂu-
orescence using ethanol–ﬁxed human neutrophils, or by antigen
speciﬁc assays using commercially available ELISA or bead-based
multiplex assays, which used puriﬁed human ANCA antigens. Pa-
tients who are ANCA positive were subclassiﬁed by ANCA speci-
ﬁcity to either myeloperoxidase or PR3 antigens. In patients who
tested positive by ﬂuorescence testing but negative by antigen-
speciﬁc assay, those with a perinuclear indirect immunoﬂuores-
cence pattern were assigned to the MPO group and those with a
cytoplasmic pattern to the PR3 group.
Following identiﬁcation of cases, the case notes, pathology, and
laboratory records were reviewed to collect data using an electronic
database on details of clinical presentation, treatment, and outcomes.
Patients were followed up from presentation until last clinical
encounter prior to December 31, 2014. RRT at presentation was
deﬁned by the need for acute dialysis during the ﬁrst hospital admis-
sion. ESRD was deﬁned by a sustained requirement for RRT that did
not recover during follow-up or before death. GFR was estimated by
theModiﬁedDiet inRenalDisease calculation.38 Relapseswere deﬁned
by an increase or recurrence in disease activity requiring augmented
immunotherapy. For histopathological analysis, we reviewed original
renal biopsy reports. We deﬁned “crescentic” glomeruli by theKidney International (2017) 92, 693–702presence of cellular, ﬁbrocellular, or ﬁbrous crescents. Synchronous
crescent formation was deﬁned by the presence of uniformly aged
glomerular crescents in the biopsy, whereas a mix of cellular, ﬁbro-
cellular, or ﬁbrous crescents deﬁned “asynchronous” crescent forma-
tion. Obsolete glomeruli, and those with segmental scars, were
included in the category of “sclerotic” glomeruli. “Normal” glomeruli
included those with minor mesangial or ischemic changes only,
without signiﬁcant proliferation, scarring, or crescent formation.
We compared baseline clinical features and long-term outcomes
between all 3 diagnoses. In addition, we performed more detailed
comparison of histopathology and treatment in the single-positive
anti-GBM and double-positive groups. Continuous data were
regarded as nonparametric. For comparison of continuous variables,
Mann-Whitney (2 groups) and Kruskal–Wallis with post hoc Dunn’s
test (more than 2 groups) were used to ascertain differences between
individual groups. For comparison of categorical variables between
groups, chi-square test was used. Log-rank test was used to ascertain
unadjusted survival differences and plotted as Kaplan–Meier curves.
Cox proportional regression analysis was used to ascertain propor-
tional hazards ratio of factors associated with categorical outcomes
(death, ESRD progression, and death or ESRD progression as a
composite outcome). Covariates included in the multivariable Cox
proportional regression analysis included diagnosis, age, RRT at
presentation, and lung hemorrhage at presentation. For the diagnosis
subgroup in the Cox regression analyses, diagnosis was entered into
the model as a categorical predictor, with double-positive chosen as
the reference. The analysis was repeated with AAV as the reference
subgroup to evaluate differences between AAV and anti-GBM dis-
ease. Proportionality assumption was met for covariates included in
the Cox regression analysis. Data are presented as hazards ratios
(conﬁdence interval; P value). Graphs were constructed and statis-
tical analysis performed using Prism 5.0 (GraphPad Software, La
Jolla, CA) and SPSS version 22.0 (IBM Corp., Armonk, NY).
As this was a retrospective study and all treatment decisions were
made prior to our assessment, research ethics approval was not
required for this report.DISCLOSURE
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